In a case that underscores the aggressive IP enforcement posture of leading aesthetic device manufacturers, BTL Industries, Inc. filed suit against Muneca Curves LLC in the Eastern District of New York on March 5, 2024, asserting infringement of U.S. Patent No. US10478634B2 — the patent behind the company’s flagship EMSCULPT® non-invasive body-contouring platform. The case closed on August 1, 2024, after just 149 days, when BTL voluntarily dismissed the action without prejudice pursuant to a confidential settlement agreement, leaving no public record of damages or injunctive relief terms.

For IP professionals and medical device innovators, this case is a signal: the non-invasive aesthetic device market is increasingly patent-contested, and operators — particularly smaller wellness and body-contouring businesses — face meaningful litigation exposure when deploying or advertising competing or unlicensed technology. The settlement outcome, while confidential, reflects the leverage that holders of FDA-cleared device patents carry against smaller market participants and highlights critical FTO considerations for anyone operating in this space.

Case Overview

The Parties

The Patent at Issue

U.S. Patent No. US10478634B2 covers the core technology underlying BTL’s EMSCULPT® device — a non-invasive, FDA-cleared aesthetic treatment system that uses high-intensity focused electromagnetic (HIFEM) energy to induce supramaximal muscle contractions for body contouring and fat reduction. The patent protects the device’s method and apparatus for delivering controlled electromagnetic stimulation to targeted muscle groups without surgery or anesthesia. In real-world application, the technology is used in clinical and aesthetic practices for abdominal sculpting, buttock lifting, and muscle toning treatments.

• • US10478634B2

Legal Representation

Plaintiff Counsel: Dunnington Bartholow & Miller LLP (lead: Padmaja Chinta)

Litigation Timeline & Procedural History

BTL Industries filed this action in the Eastern District of New York — a court with an active patent docket and experience handling technology and medical device disputes — on March 5, 2024. The choice of EDNY is strategically significant, as it placed the burden on Muneca Curves, a locally operating business, to respond in a federal venue with substantial litigation costs, even before the merits were addressed. This is a first-instance district court case, meaning it was filed at the trial level with full discovery and procedural obligations available to both parties.

At just 149 days from filing to closure, the case resolved far faster than the median patent infringement case in federal court, which typically spans two to four years. The case terminated via voluntary dismissal without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i), the mechanism available to a plaintiff before the defendant files an answer or motion for summary judgment. The dismissal was executed concurrently with a confidential settlement agreement, suggesting BTL achieved its commercial or licensing objectives early — likely through a cease-and-desist, licensing arrangement, or payment — before significant judicial resources were expended. No defendant legal representation is on record, which may have accelerated settlement dynamics.

The Verdict & Legal Analysis

Outcome

The case was terminated on August 1, 2024, via voluntary dismissal without prejudice filed by plaintiff BTL Industries, Inc., pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i) and a confidential settlement agreement executed between the parties. No damages award, no injunctive relief, and no claim construction rulings were issued by the court. Because the dismissal was without prejudice, BTL retains the right to refile claims arising from the same patent and underlying conduct should the settlement terms be breached.

Verdict Cause Analysis

The infringement action was grounded in BTL’s assertion of patent rights in its EMSCULPT® technology — the following key legal grounds and dynamics shaped how this case unfolded and resolved:

• BTL alleged infringement of US10478634B2, covering the HIFEM-based electromagnetic body-contouring apparatus and methods underlying the EMSCULPT® device, asserting that Muneca Curves was using or offering services with infringing technology.
• The voluntary dismissal under Rule 41(a)(1)(A)(i) indicates Muneca Curves had not yet filed an answer or a Rule 12 motion, meaning BTL was entitled to dismiss unilaterally without court approval — a procedural window that enabled rapid, low-cost exit once settlement was reached.
• The without-prejudice designation preserves BTL’s full legal rights under the patent; if Muneca Curves resumes infringing activity or defaults on settlement obligations, BTL can reinitiate litigation without being barred by res judicata.
• The absence of any recorded defendant legal representation suggests Muneca Curves may have been unrepresented or retained counsel privately without formal court filing, a factor that often accelerates settlement in favor of the patent holder.

Legal Significance

1. 1. This case reinforces that U.S. Patent No. US10478634B2 is an actively enforced asset: BTL has demonstrated willingness to file suit in federal court against even small downstream service providers, signaling a zero-tolerance licensing posture that competitors and service operators must account for in their IP risk assessments.
2. 2. The Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice, executed alongside a confidential settlement, creates no claim construction record, no invalidity findings, and no public license terms — meaning the patent’s scope remains legally untested and commercially potent for future enforcement actions.
3. 3. The case highlights a growing trend in medical device patent enforcement where OEM manufacturers target not just competing device makers but also aesthetic clinics, wellness centers, and small service businesses as end-users of allegedly infringing technology, expanding the litigation risk surface well beyond traditional competitor disputes.

Strategic Takeaways

For Patent Attorneys:

• When representing patent holders in medical device enforcement, early-stage Rule 41(a)(1)(A)(i) dismissals paired with confidential settlements preserve the patent’s enforceability and claim scope — counsel should build this off-ramp into litigation strategy from the outset to maximize leverage without expending litigation budget.
• The absence of defendant representation on record is a material factor in accelerating settlement; counsel monitoring competitive markets should advise clients to file promptly against unrepresented infringers before they retain counsel and harden their position.
• Without-prejudice dismissals in patent infringement actions should always include carefully drafted breach provisions and reinstatement triggers to ensure the patent holder retains full enforcement rights if settlement obligations are not honored.
• Practitioners advising aesthetic device companies or service providers should conduct claim mapping against US10478634B2 and BTL’s broader patent family before clients deploy any electromagnetic body-contouring technology, as BTL has demonstrated active enforcement intent.

For IP Professionals:

• In-house IP teams at medical device companies should monitor BTL’s enforcement activity against downstream service providers as a benchmark for their own licensing and enforcement programs — the EDNY filing against a small LLC demonstrates the value of asserting patents broadly across the value chain, not just against direct competitors.
• Companies operating in the non-invasive aesthetics space should audit their product and service portfolios against US10478634B2 and related HIFEM patents, and consider proactive licensing conversations with BTL before receiving a demand letter or complaint.

For R&D Teams:

• R&D teams developing non-invasive electromagnetic muscle stimulation or body-contouring devices must treat US10478634B2 as a key prior art and FTO obstacle — design-around strategies should focus on differentiating electromagnetic field delivery parameters, applicator geometry, and treatment protocols from the claims of BTL’s granted patent.
• Teams building products for aesthetic clinics or wellness centers should recognize that end-user service providers are now litigation targets, not just device manufacturers — engineering teams should document non-infringing use cases and prepare clear technical differentiation materials that can support freedom-to-operate arguments if needed.